Raj Parekh, MA DPhil

Raj brings over 25 years of experience as an entrepreneur and venture investor in the life sciences. During an academic career at Oxford University, Dr Parekh co-founded Oxford GlycoSciences plc. He has been a General Partner at Advent Life Sciences since 2005, and has served on the Board of several Biotechnology Companies in the US and Europe including Celldex Therapeutics, Avila Therapeutics, EUSA Pharma, Cellnovo, and F2G. He is Chairman of Galapagos nv and also a member of the Supervisory Board of the Novartis Venture Fund. He received his BA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford.

Javier García, MBA

Mr. García is former Eli Lilly and Co.’s Vice President of Business Development for the Biomedicines Business Unit. He had responsibilities for a broad area within the Lilly portfolio (Neurosciences, Cardiovascular, Autoimmune, Urology and Bone). His scope of work also included the search for new therapeutic areas of interest to Lilly in the US, Japan, Europe, Canada and Australia. Mr. García joined Eli Lilly and Company in 1988 and has held several positions with the company. Initially as IT Director, he then went on to take global leadership positions in IT in the Medical and Regulatory groups. From 2001 to 2008 he led the global Sales and Marketing IT organization. He also held different positions in the Sales organization in the US.

Mr. García is also serving as a member of the Board of Directors for two organizations: the National Alliance for Hispanic Health (the premier US non profit organization that focuses on improving the health and well-being of Hispanics) and the Health Foundation for the Americas. Mr. García received his MBA from the “Universidad de Comillas (Madrid)” in 1990, and holds a Bachelor on Statistics and Operation Research from the Universidad Complutense, Madrid.

Damià Tormo, PhD, MBM

Dr. Tormo has been co-founder and advisor for several biotech companies. Among these companies, he co-founded and was CEO of Bioncotech Therapeutics, a spin-off from the Spanish National Cancer Research Center (CNIO), Restaura Biotech SL (a Polytechnic University of Valencia spin-off), Frozen Shard SL and Polymer Therapeutic Solutions SL. He is also co-founder and partner of Biocapital Advisors SL.

Dr. Tormo holds a BSc from the University of Valencia, Spain, a PhD in Immunology and Molecular Genetics from the University of Bonn, Germany, and a master’s degree in biotechnology management (MBM) from IE Business School, Madrid. He was a post-doc fellow at the University of Michigan. Additionally, he has extensive scientific experience endorsed by scientific publications in prestigious journals. He has recieved scholarships and different awards related to innovation and entrepreneurship such as MIT’s TR35 Spain 2011, Emprendedores sXXI from La Caixa and the Biogen-Idec Foundation award.

Gino Santini, MBA

In 2010, Mr. Santini retired from distinguished career with Eli Lilly and Company that spanned nearly three decades. During his tenure at Lilly, Mr. Santini held various leadership positions of increasing responsibility, including manager of various international regions, senior vice president of corporate strategy and policy, president of the women’s health franchise and president of U.S. operations. Mr. Santini capped his career at Lilly as a member of the company’s executive committee and as the senior vice president of corporate strategy and business development. Mr. Santini currently serves on the Board of Directors of Allena Pharmaceuticals, Intarcia Therapeutics, Collegium Pharmaceutical, Sorin Group, Horizon Pharma and AMAG Pharmaceuticals.

Mr. Santini, fluent in four languages, holds an undergraduate degree in mechanical engineering from the University of Bologna and a master’s in business administration from the University of Rochester.

Rob Armstrong, PhD

Robert W. Armstrong, Ph.D., was the vice president of Global External Research and Development for Eli Lilly and Company from 2006 to 2012 and a member of the Senior Management Team. Previously, he was vice president of Discovery Chemistry Research at the same company. Prior to joining Lilly in November 1999, Armstrong had been director and head of Small Molecule Drug Discovery at Amgen, Inc.

He received a bachelor of science degrees in chemistry and biochemistry from the University of California at San Diego in 1979 and a doctorate degree in chemistry from Colorado State University in 1984. Upon completion of an NIH postdoctoral fellowship at Harvard University in 1986, was a faculty member in the Department of Chemistry and Biochemistry at the University of California at Los Angeles, where he remains an adjunct faculty member.

In memoriam: Henri A. Termeer

Henri A. Termeer, former CEO, Chairman and President of Genzyme Corporation. Mr. Termeer was appointed president of Genzyme in 1983 became its chief executive officer in 1985 and chairman in 1988. He retired from Genzyme in June 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Widely acknowledged for his contributions to the biotechnology industry and health care field, Mr. Termeer was active in the areas of humanitarian assistance, policy issues and innovation in providing access to health care. Mr. Termeer was a Board member of Massachusetts Institute of Technology Corporation and served on its Executive Committee, a director of Massachusetts General Hospital, board member of Partners HealthCare, and a member of the Board of Fellows of Harvard Medical School. He sat on the boards of Biotechnology Industry Organization (BIO), Life Sciences Foundation, Boston Ballet, Museum of Science, Project Hope and WGBH. He also served on the boards of Abiomed, Inc., AVEO Pharmaceuticals, Moderna Therapeutics, ProQR Therapeutics, and Verastem, Inc. Mr. Termeer was a member of the board of the Federal Reserve Bank of Boston from 2007-2011 and its chairman from 2010-2011. Mr. Termeer studied economics at the Economische Hogeschool (Erasmus University, The Netherlands) and earned an M.B.A from the Darden Business School at the University of Virginia.